Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPI | P34949 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1302303 | 1.00 | MPI (0.39) | MPI | |
| SCHEMBL28000832 | 1.00 | MPI (0.39) | MPI | |
| SCHEMBL9499191 | 0.93 | MPI (0.41) | MPI | |
| SCHEMBL3501009 | 0.81 | ALDH1A1 (0.42) | — | |
| SCHEMBL10489052 | 0.78 | MPI (0.39) | MPI | |
| SCHEMBL565806 | 0.78 | MPI (0.39) | MPI | |
| SCHEMBL4160815 | 0.78 | MPI (0.39) | MPI | |
| SCHEMBL458492 | 0.78 | MPI (0.39) | MPI | |
| SCHEMBL2889691 | 0.78 | MPI (0.39) | MPI | |
| SCHEMBL1586372 | 0.78 | MPI (0.39) | MPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4438734-A2 | REPROGRAMMING OF CELLS TO A NEW FATE | The Scripps Research Institute (US) | 2024-10-02 | — | — | EP | disclosed |
| EP-3399026-B1 | REPROGRAMMING OF CELLS TO A NEW FATE | SCRIPPS RESEARCH INST (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20210189348-A1 | REPROGRAMMING OF CELLS TO A NEW FATE | THE SCRIPPS RESEARCH INSTITUTE | 2021-06-24 | — | — | US | disclosed |
| US-10934528-B2 | Reprogramming of cells to a new fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-03-02 | — | — | US | disclosed |
| US-10308912-B2 | Reprogramming of cells to a new fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-06-04 | — | — | US | disclosed |
| EP-3399026-A1 | REPROGRAMMING OF CELLS TO A NEW FATE | The Scripps Research Institute (US) | 2018-11-07 | — | — | EP | disclosed |
| EP-2580320-B1 | REPROGRAMMING OF CELLS TO A NEW FATE | SCRIPPS RESEARCH INST (US) | 2018-08-01 | — | — | EP | disclosed |
| US-20170159019-A1 | REPROGRAMMING OF CELLS TO A NEW FATE | THE SCRIPPS RESEARCH INSTITUTE | 2017-06-08 | — | — | US | disclosed |
| US-9556417-B2 | Reprogramming of cells to a new fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160264938-A1 | Reprogramming of Cells to a New Fate | THE SCRIPPS RESEARCH INSTITUTE | 2016-09-15 | — | — | US | disclosed |
| US-20090324682-A1 | Medical stent provided with inhibitors of atp synthesis | INTERSTITIAL THERAPEUTICS (CH) | 2009-12-31 | — | — | US | disclosed |
| EP-1789107-B1 | MEDICAL STENT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | INTERSTITIAL THERAPEUTICS (CH) | 2009-05-27 | — | — | EP | disclosed |
| US-20070293439-A1 | Methods and Compositions for Treating Hyperglycemic, Hyperlipidemic, or Hyperinsulinemic Disorders | OHIO UNIVERSITY (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070292478-A1 | Medical Implant Provided with Inhibitors of Atp Synthesis | INTERSTITIAL THERAPEUTICS (CH) | 2007-12-20 | — | — | US | disclosed |
| EP-1789030-A2 | MEDICAL IMPLANT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | Interstitial Therapeutics (CH) | 2007-05-30 | — | — | EP | disclosed |
| EP-1789107-A2 | MEDICAL STENT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | Interstitial Therapeutics (CH) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006034468-A9 | METHODS AND COMPOSITIONS FOR TREATING HYPERGLYCEMIC, HYPERLIPIDEMIC, OR HYPERINSULINEMIC DISORDERS | UNIV OHIO (US) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006034468-A2 | METHODS AND COMPOSITIONS FOR TREATING HYPERGLYCEMIC, HYPERLIPIDEMIC, OR HYPERINSULINEMIC DISORDERS | OHIO UNIVERSITY (US) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006024488-A2 | MEDICAL STENT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | disclosed |
| WO-2006024492-A2 | MEDICAL IMPLANT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090324682-A1 | Medical stent provided with inhibitors of atp synthesis | ATP5ME, ATP5F1A, ATP5MG | MPI 193/4885 |
| US-20070293439-A1 | Methods and Compositions for Treating Hyperglycemic, Hyperlipidemic, or Hyperinsulinemic Disorders | PNLIP, LIPC, LIPA | MPI 139/4885 |
| US-20070292478-A1 | Medical Implant Provided with Inhibitors of Atp Synthesis | ATP5F1A, ATP5ME, ATP5MG | MPI 365/4885 |
| US-10934528-B2 | Reprogramming of cells to a new fate | ALPG, POU5F1, POU2F1 | MPI 1112/4885 |
| US-20170159019-A1 | REPROGRAMMING OF CELLS TO A NEW FATE | ALPG, POU5F1, POU2F1 | MPI 1112/4885 |
| US-20210189348-A1 | REPROGRAMMING OF CELLS TO A NEW FATE | ALPG, POU5F1, POU2F1 | MPI 1112/4885 |
| US-10308912-B2 | Reprogramming of cells to a new fate | ALPG, POU5F1, POU2F1 | MPI 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.